CLINICAL RESEARCH STUDIES

Clinical Research Studies

Southern Vitreoretinal Associates has an established history of conducting and developing clinical research protocols in the treatment of vitreoretinal diseases and disorders. We work in partnership with study volunteers, study sponsors, and the FDA toward the development of improved treatments for vitreoretinal issues. Southern Vitreoretinal Associates is committed to
conducting accurate and timely clinical trials with an emphasis on bringing the latest research developments to our region.

Southern Vitreoretinal Associates offer patients the opportunity to participate in clinical trials conducted at our facility. Experimental therapy for select conditions is available, and may be a valuable alternative to traditional treatments. By participating in a clinical trial, patients help to further increase medical technology. Clinical trials turn biomedical research into state-of-the-art health care. Through the research collected in the clinical trials, new and/or better treatments can be made available to patients with a particular condition.

Our experienced clinical study coordinator works closely with patients and our physicians on a variety of clinical trials. Our physicians are involved as primary or sub-investigators in ongoing research projects. If you are interested in being considered for a research project, please advise your physician.


* Indicates Completed Study

Upcoming Clinical Trials

Sponsor
Indication
Criteria
Drug Delivery Length

Genentech
(HORIZON)
Phase III

CNV subjects previously treated with rhuFab

Only open to subjects who have completed the treatment phase of a Genentech -sponsored Ranibizumab Study

rhuFab V2
Ranibizumab
(Lucentis)

Intravitreal injection
Up to 24 Months

Genentech
(SAILOR)
Phase III

Choroidal
Neovascular
Membrane

Naïve and previously treated subjects with CNV secondary to AMD

rhuFab V2
Ranibizumab (Lucentis)

Intravitreal injection

12 months

Allergan
(Posurdex A)

Macular Edema due to BRVO or CRVO

>18 yrs old, VA decrease attributable to edema, Retinal thickness of > 300 mm by OCT

700mg Dexamethasone
vs
350 mg Dexamethasone
(DEX)
vs sham

Injection using Posterior Segment Drug Delivery System Applicator
(DEX PS DDS)

12 months
(6 months masked, 6 months open-label)

Allergan
(Posurdex B)

Diabetic Macular Edema

> 18 yrs old, Previously treated with any medical treatment or laser, OR no prior laser tx, Ret. thickness > 300 mm by OCT

700mg Dexamethasone
vs
350 mg Dexamethasone
(DEX)
vs sham

Injection using Posterior Segment Drug Delivery System Applicator
(DEX PS DDS)

36 months

Bausch & Lomb
Phase 1b

Creation of a PVD

> 18 yo, who would benefit from a PVD; ie MH, NPDR, etc.

Plasmin
Intravitreal injection
6 months

 

© 2006 Southern Vitreoretinal Associates, P.A.